These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35401257)

  • 1. Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D
    Kiss B; Krámos B; Laszlovszky I
    Front Psychiatry; 2022; 13():785592. PubMed ID: 35401257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition.
    Simpson EH; Winiger V; Biezonski DK; Haq I; Kandel ER; Kellendonk C
    Biol Psychiatry; 2014 Nov; 76(10):823-31. PubMed ID: 24387821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
    Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
    Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.
    Kiss B; Laszlovszky I; Krámos B; Visegrády A; Bobok A; Lévay G; Lendvai B; Román V
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33466844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
    Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B
    Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of dopamine D
    Calabrese F; Tarazi FI; Racagni G; Riva MA
    CNS Spectr; 2020 Jun; 25(3):343-351. PubMed ID: 31010452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
    Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
    Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.
    Seeman P
    CNS Neurosci Ther; 2011 Apr; 17(2):118-32. PubMed ID: 20560996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
    Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
    J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.
    Leysen JE; Janssen PM; Schotte A; Luyten WH; Megens AA
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S40-54. PubMed ID: 7530377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.
    Neisewander JL; Cheung TH; Pentkowski NS
    Neuropharmacology; 2014 Jan; 76 Pt B(0 0):301-19. PubMed ID: 23973315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro.
    McCormick PN; Kapur S; Graff-Guerrero A; Raymond R; Nobrega JN; Wilson AA
    Neuropsychopharmacology; 2010 Jul; 35(8):1826-35. PubMed ID: 20410873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current use of atypical antipsychotics.
    Müller-Spahn F
    Eur Psychiatry; 2002 Aug; 17 Suppl 4():377s-384s. PubMed ID: 23573608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
    Bressan RA; Erlandsson K; Jones HM; Mulligan RS; Ell PJ; Pilowsky LS
    J Clin Psychopharmacol; 2003 Feb; 23(1):5-14. PubMed ID: 12544369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.